Childhood burkitt lymphoma: treatment outcomes, survival, and mortality predictors at two tertiary hospitals in Tanzania
- 1Department of Pediatrics, Kilimanjaro Christian Medical Centre
- 2Department of Surgery, Catholic University of Health and Allied Sciences
Abstract
Background Burkitt lymphoma (BL) is an aggressive B-cell lymphoma predominantly affecting children in sub-Saharan Africa. It constitutes 50–70% of pediatric non-Hodgkin lymphomas in the region. In Tanzania, understanding the treatment outcomes and one-year survival rates at two major oncology centers can inform strategies to enhance survival. Methodology This retrospective cohort study analyzed children under 18 diagnosed with Burkitt lymphoma and treated at two tertiary care hospitals between January 2020 and December 2022. The study utilized Stata 18 to analyze data from medical records, focusing on demographic and clinical characteristics, Kaplan-Meier survival analysis, and Cox proportional hazards models to identify mortality predictors. Results The study analyzed 72 children with Burkitt lymphoma (mean age: 5.8 years), predominantly male (70.8%), with 52.8% from rural areas. Tumor sites were mainly mandibular (47.2%) and abdominal (41.7%). Treatment outcomes varied between hospitals: Kilimanjaro Christian Medical Centre had a higher complete remission rate (61.3%) compared to BMC (36.6%), while BMC experienced higher relapse (19.5%) and treatment abandonment rates (22.0%) than KCMC (6.5% and 3.2%, respectively). The one-year post-treatment survival rate was 75% overall, with a significantly longer mean survival time at KCMC (37.1 months) versus BMC (16.4 months). Key predictors of mortality included bone marrow involvement, adjusted hazard ratio (AHR) = 32.48 and CNS involvement (AHR = 34.00, 95% CI). Conclusion The study reveals a 75% one-year survival rate for children with Burkitt lymphoma in Tanzania. However, this reflects short-term (one-year) survival and cannot be directly compared with the WHO Global Initiative for Childhood Cancer 2030 target, which refers to five-year overall survival. However, high treatment abandonment, relapse, and death rates, along with low complete remission rates, pose significant challenges. Key factors contributing to poor prognosis include CNS and bone marrow involvement. The study recommends comprehensive interventions, improved care access, and exploring alternative treatments like stem cell transplantation.
Related
- Incidence and predictors of early neonatal mortality among neonates admitted to neonatal intensive care units in public general hospitals in Northwest Ethiopia: a multicenter prospective cohort study.
- REDUCTION IN EARLY TREATMENT-RELATED MORTALITY IN THE NATIONAL BRAZILIAN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA PROTOCOL (GBTLI-LLA 2021)
- Predictors of Preeclampsia and Pregnancy Associated Outcomes Among Pregnant Women: A Prospective Cohort Study in Selected Hospitals in Kiambu County, Kenya
- Incidence and predictors of acute decompensation in adult patients with cirrhosis: a retrospective cohort study at the University of Gondar comprehensive Specialized Hospitals, Northwest Ethiopia, 2025
- High Mortality in Adults With Community-Acquired Pneumonia Admitted to Hospitals in South Africa Before and During the COVID-19 Pandemic, Stratified by HIV Serostatus and Viral Load: Data From a Prospective Cohort Study (2019–2021)
BibTeX
@article{nkya2026childhood,
title = {{Childhood burkitt lymphoma: treatment outcomes, survival, and mortality predictors at two tertiary hospitals in Tanzania}},
author = {Haji Nkya and Aisa Shayo and Dennis Machaku and Blandina T. Mmbaga and Grace Kinabo and Esther Majaliwa},
journal = {BMC Pediatrics},
year = {2026},
month = jun,
doi = {10.1186/s12887-026-07064-2},
url = {https://doi.org/10.1186/s12887-026-07064-2},
note = {CC BY},
}
RIS
TY - JOUR
TI - Childhood burkitt lymphoma: treatment outcomes, survival, and mortality predictors at two tertiary hospitals in Tanzania
AU - Haji Nkya
AU - Aisa Shayo
AU - Dennis Machaku
AU - Blandina T. Mmbaga
AU - Grace Kinabo
AU - Esther Majaliwa
PY - 2026
DA - 2026/06/01
JO - BMC Pediatrics
DO - 10.1186/s12887-026-07064-2
UR - https://doi.org/10.1186/s12887-026-07064-2
AB - Background Burkitt lymphoma (BL) is an aggressive B-cell lymphoma predominantly affecting children in sub-Saharan Africa. It constitutes 50–70% of pediatric non-Hodgkin lymphomas in the region. In Tanzania, understanding the treatment outcomes and one-year survival rates at two major oncology centers can inform strategies to enhance survival. Methodology This retrospective cohort study analyzed children under 18 diagnosed with Burkitt lymphoma and treated at two tertiary care hospitals between January 2020 and December 2022. The study utilized Stata 18 to analyze data from medical records, focusing on demographic and clinical characteristics, Kaplan-Meier survival analysis, and Cox proportional hazards models to identify mortality predictors. Results The study analyzed 72 children with Burkitt lymphoma (mean age: 5.8 years), predominantly male (70.8%), with 52.8% from rural areas. Tumor sites were mainly mandibular (47.2%) and abdominal (41.7%). Treatment outcomes varied between hospitals: Kilimanjaro Christian Medical Centre had a higher complete remission rate (61.3%) compared to BMC (36.6%), while BMC experienced higher relapse (19.5%) and treatment abandonment rates (22.0%) than KCMC (6.5% and 3.2%, respectively). The one-year post-treatment survival rate was 75% overall, with a significantly longer mean survival time at KCMC (37.1 months) versus BMC (16.4 months). Key predictors of mortality included bone marrow involvement, adjusted hazard ratio (AHR) = 32.48 and CNS involvement (AHR = 34.00, 95% CI). Conclusion The study reveals a 75% one-year survival rate for children with Burkitt lymphoma in Tanzania. However, this reflects short-term (one-year) survival and cannot be directly compared with the WHO Global Initiative for Childhood Cancer 2030 target, which refers to five-year overall survival. However, high treatment abandonment, relapse, and death rates, along with low complete remission rates, pose significant challenges. Key factors contributing to poor prognosis include CNS and bone marrow involvement. The study recommends comprehensive interventions, improved care access, and exploring alternative treatments like stem cell transplantation.
SN - 1471-2431
ER -